Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
JAK3
REST API REST API
Homo sapiens
JAK3 is differentially expressed in 299 experiments: 124 organism parts: bone marrow, kidney, ... (122 more);, 246 disease states: normal, chronic lymphocytic leukemia, ... (244 more);, 95 cell types 365 cell lines 40 compound treatments and 80 other conditions.
Synonyms L-JAK, LJAK, JAKL, JAK-3, JAK3_HUMAN
Orthologs jak3 (Danio rerio)   Jak3 (Mus musculus)   E1BEL4_BOVIN (Bos taurus)   Jak3 (Rattus norvegicus)   Q4H3A3_CIOIN (Ciona intestinalis)   PR2 (Drosophila melanogaster)   jak3 (Xenopus laevis)   JAK3 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term endomembrane system, cytosol, elevation of cytosolic calcium ion concentration, protein binding, cytoskeleton, cytokine-mediated signaling pathway, cytoplasm, innate immune response, membrane, tyrosine phosphorylation of STAT protein, peptidyl-tyrosine phosphorylation, protein tyrosine kinase activity, ATP binding, positive regulation of transcription from RNA polymerase II promoter, nucleotide binding, protein serine/threonine kinase activity, positive regulation of calcium ion transport, non-membrane spanning protein tyrosine kinase activity, protein kinase activity, intracellular protein kinase cascade, regulation of apoptosis, positive regulation of immune response, B cell differentiation, tyrosine phosphorylation of Stat5 protein, negative regulation of T-helper 1 cell differentiation, negative regulation of T cell activation, negative regulation of thymocyte apoptosis, positive regulation of anti-apoptosis, response to interleukin-2, response to interleukin-4, response to interleukin-9, positive regulation of activated T cell proliferation, negative regulation of interleukin-10 production, T cell homeostasis, response to interleukin-15, enzyme linked receptor protein signaling pathway, negative regulation of interleukin-12 production, JAK-STAT cascade involved in growth hormone signaling pathway, protein autophosphorylation, protein phosphorylation, STAT protein import into nucleus, regulation of T cell apoptosis, negative regulation of FasL biosynthetic process, negative regulation of dendritic cell cytokine production
InterPro Term SH2, Prot_kinase_cat_dom, Band_41_domain, FERM_domain, Tyr_kinase_non-rcpt_Jak/Tyk2, Tyr_kinase_non-rcpt_Jak3, Ser/Thr_kinase_dom, Tyr_kinase_cat_dom, Ser-Thr/Tyr_kinase, Se/Thr_kinase-like_dom
UniProt Accession P52333, Q9UMU1, Q6LD09, Q8N1E8
Gene-Disease Assocation SEVERE COMBINED IMMUNODEFICIENCY, AUTOSOMAL RECESSIVE, T CELL-NEGATIVE,
Search EB-eye ENSG00000105639
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-AFMX-5, E-GEOD-6573, E-MTAB-24, ... (23 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-3860, E-GEOD-5258, E-GEOD-19639, E-GEOD-2450, ... (35 experiments)

Factor Value U/D Experiments
BT474
3
E-MTAB-37, E-MTAB-62, E-MEXP-440
MCF-7
3
E-GEOD-20081, E-GEOD-19639, E-GEOD-5823
primary culture
2
E-GEOD-2450, E-GEOD-1657
HL-60
1
2
E-GEOD-24147, E-MTAB-37, E-GEOD-5258
H720
1
E-GEOD-3202
GM15510
1
E-GEOD-22639
359 more value(s).


Cell type

studied in E-GEOD-20193, E-GEOD-21612, E-GEOD-21668, E-GEOD-3920, E-MEXP-750, ... (54 experiments)

Factor Value U/D Experiments
plasma cell
2
E-MEXP-2360, E-GEOD-6691
CD4+ T cell
1
2
E-GEOD-16190, E-MTAB-24, E-AFMX-5
secretory cell
1
E-GEOD-3998
immortalized cell culture
1
E-GEOD-14990
hematopoietic stem cell
1
E-MEXP-1403
spheroid
1
E-GEOD-21612
89 more value(s).


Disease state

studied in E-GEOD-1615, E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-GEOD-1577, ... (70 experiments)

Factor Value U/D Experiments
gastric carcinoma
3
E-MTAB-37, E-GEOD-2685, E-GEOD-15460
Crohn's disease
2
E-GEOD-3365, E-GEOD-6731
neuroblastoma
2
E-MTAB-37, E-MTAB-62
T-cell acute lymphoblastic leukemia
2
E-MTAB-37, E-GEOD-1577
acute lymphoblastic leukemia
2
E-MTAB-37, E-MTAB-62
acute promyelocytic leukemia
2
E-MTAB-62, E-GEOD-995
240 more value(s).


Compound treatment

studied in E-GEOD-5258, E-GEOD-15205, E-GEOD-697, E-GEOD-5824, E-GEOD-5099, ... (24 experiments)

Factor Value U/D Experiments
none
4
6
E-MEXP-1958, E-GEOD-412, E-MEXP-1601, E-MEXP-1230, E-GEOD-995, ... (10 experiments)
ethanol
2
E-MEXP-2241, E-GEOD-3113
glutamine
2
E-MEXP-941, E-MEXP-1335
lipopolysaccharide
2
E-MEXP-1958, E-GEOD-4984
U0126
1
E-GEOD-697
TNF
1
E-GEOD-15205
34 more value(s).


Age at onset

studied in E-GEOD-21521

Factor Value U/D Experiments
LT6
1
1
E-GEOD-21521


Agent
studied in E-GEOD-19519

Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Clinical history
studied in E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-GEOD-21374, E-GEOD-21589, ... (7 experiments)

Clinical info
studied in E-MEXP-1828, E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-GEOD-19348, ... (12 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-2171, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-19743, E-GEOD-5999, E-GEOD-3140, E-GEOD-4667, E-MEXP-2283, ... (6 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-GEOD-19665, E-GEOD-1751

Environmental stress
studied in E-GEOD-1643

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-MEXP-1482, E-GEOD-7578, E-GEOD-17385, E-GEOD-20847, ... (6 experiments)

Genotype
studied in E-GEOD-22056, E-GEOD-3494, E-GEOD-2466, E-GEOD-17476, E-TABM-321, ... (10 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-5681, E-GEOD-7011, E-MEXP-2657, E-GEOD-20540, E-GEOD-22278, ... (13 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276, E-GEOD-20194, E-GEOD-16716 ... (5 experiments)

Individual
studied in E-TABM-325, E-MTAB-197, E-GEOD-2466, E-MEXP-2069, E-GEOD-1926, ... (38 experiments)

individual id
studied in E-GEOD-19519

Infection
studied in E-GEOD-2405, E-GEOD-12108, E-GEOD-12254, E-MEXP-561, E-GEOD-980 ... (5 experiments)

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214, E-GEOD-22056

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-MEXP-958, E-GEOD-9171

Media
studied in E-GEOD-21612

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801, E-TABM-84

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

Performer
studied in E-GEOD-2004, E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-19703, E-GEOD-22309, E-GEOD-1657, E-GEOD-1460, E-MEXP-1403 ... (5 experiments)

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Progression free survival of days
studied in E-GEOD-5851

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246 ... (5 experiments)

Replicate
studied in E-GEOD-10896

RNAi
studied in E-MEXP-1509, E-MEXP-101, E-GEOD-3697, E-MEXP-1857

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-GEOD-21374

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-2466, E-GEOD-7307, E-TABM-147

Stimulation
studied in E-GEOD-4883, E-GEOD-20114, E-GEOD-11886

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276

Tissue
studied in E-GEOD-30573

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-22152, E-GEOD-16837, E-GEOD-19246, E-GEOD-12198

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-4922

Vehicle
studied in E-GEOD-5258

Processing time: 0.484 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM